CA2263149A1 - Methodes de diagnostic de la migraine accompagnee d'aura, de depression et d'angoisse, a partir de variations alleliques de genes dopaminergiques - Google Patents

Methodes de diagnostic de la migraine accompagnee d'aura, de depression et d'angoisse, a partir de variations alleliques de genes dopaminergiques Download PDF

Info

Publication number
CA2263149A1
CA2263149A1 CA002263149A CA2263149A CA2263149A1 CA 2263149 A1 CA2263149 A1 CA 2263149A1 CA 002263149 A CA002263149 A CA 002263149A CA 2263149 A CA2263149 A CA 2263149A CA 2263149 A1 CA2263149 A1 CA 2263149A1
Authority
CA
Canada
Prior art keywords
drd2
alleles
migraine
syndrome
aura
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002263149A
Other languages
English (en)
Inventor
Stephen J. Peroutka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CA2263149A1 publication Critical patent/CA2263149A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes de diagnostic d'un syndrome caractérisé par des symptômes de migraine accompagnée d'aura, de dépression et/ou d'angoisse. Le diagnostic consiste à détecter un allèle d'au moins un gène dopaminergique, par ex. DRD1, DRD2, DRD3 et DAT. L'invention concerne également des méthodes de criblage d'agents thérapeutiques servant à traiter ledit syndrome, ainsi que des méthodes de traitement correspondantes.
CA002263149A 1996-08-22 1997-08-21 Methodes de diagnostic de la migraine accompagnee d'aura, de depression et d'angoisse, a partir de variations alleliques de genes dopaminergiques Abandoned CA2263149A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2439996P 1996-08-22 1996-08-22
US60/024,399 1996-08-22
US3609197P 1997-01-17 1997-01-17
US60/036,091 1997-01-17
PCT/US1997/014830 WO1998007426A1 (fr) 1996-08-22 1997-08-21 Methodes de diagnostic de la migraine accompagnee d'aura, de depression et d'angoisse, a partir de variations alleliques de genes dopaminergiques

Publications (1)

Publication Number Publication Date
CA2263149A1 true CA2263149A1 (fr) 1998-02-26

Family

ID=26698401

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002263149A Abandoned CA2263149A1 (fr) 1996-08-22 1997-08-21 Methodes de diagnostic de la migraine accompagnee d'aura, de depression et d'angoisse, a partir de variations alleliques de genes dopaminergiques

Country Status (5)

Country Link
EP (1) EP1014977A1 (fr)
JP (1) JP2001527520A (fr)
AU (1) AU737893B2 (fr)
CA (1) CA2263149A1 (fr)
WO (1) WO1998007426A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233345T3 (es) * 1999-02-22 2005-06-16 University Of Miami Valvula mini capsulorrexis.
US20010053849A1 (en) * 1999-06-16 2001-12-20 Mary Jeanne Kreek Plural biological sample arrays, and preparation and uses thereof
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550021A (en) * 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder

Also Published As

Publication number Publication date
EP1014977A4 (fr) 2000-07-05
AU737893B2 (en) 2001-09-06
JP2001527520A (ja) 2001-12-25
WO1998007426A1 (fr) 1998-02-26
EP1014977A1 (fr) 2000-07-05
AU4083797A (en) 1998-03-06

Similar Documents

Publication Publication Date Title
US10228378B2 (en) Diagnostic and therapeutic methods and products related to anxiety disorders
Johann et al. Comorbidity of alcohol dependence with attention‐deficit hyperactivity disorder: Differences in phenotype with increased severity of the substance disorder, but not in genotype (serotonin transporter and 5‐hydroxytryptamine‐2c receptor)
Furlong et al. Analysis of the monoamine oxidase A (MAOA) gene in bipolar affective disorder by association studies, meta‐analyses, and sequencing of the promoter
EP3048175B1 (fr) Polymorphismes génétiques associés à l'accident vasculaire cérébral, therapie baseé sur la detection du polymorphisme et utilisations des kits pour la determination du polymorphisme
US7695911B2 (en) Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
Zai et al. Evidence for the gamma‐amino‐butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive‐compulsive disorder
US20140134186A1 (en) Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof
CA2851510A1 (fr) Polymorphismes de nucleotide simple utiles pour predire une reponse clinique a l'acetate de glatiramere
US20060286594A1 (en) Detection of antidepressant induced mania
US20070254288A1 (en) Diagnostic methods for pain sensitivity and chronicity and for tetrahydrobiopterin-related disorders
AU737893B2 (en) Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes
AU2004258147B2 (en) Genetic marker of response to atypical antipsychotics and antidepressants and methods for use thereof
US20060228750A1 (en) Method to determine the risk for side effects of an SSRI treatment in a person
US20140088035A1 (en) Treating schizophrenia
US7736852B2 (en) Methods and compositions for treating and diagnosing mood disorders, schizophrenia, and neuro-psychiatric disorders
Nishi et al. Mutations in the Glucokinase Gene are not a Major Cause of Late‐onset Type 2 (Non‐insulin‐dependent) Diabetes Mellitus in Japanese subjects
US20070111209A1 (en) Inversion on chromosome 8p23 is a risk factor for anxiety disorders, depression and bipolar disorders
EP2594649A1 (fr) Procédé et kit pour prédire une réponse à un traitement antidépresseur
WO2014120745A1 (fr) Variants génétiques associés à une réponse au lithium dans des troubles bipolaires
KR100926269B1 (ko) 노르아드레날린 재흡수 억제제 계열 항우울제의치료성공율의 예측을 위한 노르아드레날린 수송체의유전자다형성 표지자
Kakita et al. Association of the HSPG2 Gene vvith Neuroleptic-lnduced Tardive Dyskinesia
Class et al. Patent application title: DETERMINATION OF SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT RESPONSE FOR GLATIRAMER ACETATE Inventors: Teva Pharmaceutical Industries, Ltd.(Petach-Tikva, IL) Amir Tchelet (Hod-Hasharon, IL) Fabio Macciardi (Irvine, CA, US) Joseph Levy (Kfar-Sava, IL) Assignees: Teva Pharmaceutical Industries Ltd.
US20140142150A1 (en) Treating neuropsychiatric disorders
MEISSNER et al. Variegate Porphyria 89

Legal Events

Date Code Title Description
FZDE Dead